Global Biopharma CEO/Top Executives COVID-19 Media Briefing – COVID-19 therapeutics: 3 Sept 2020
On 3 September 2020, the global biopharmaceutical industry, represented by high-level executives/ CEO’s, took part in a virtual media briefing on COVID-19 therapeutics: innovation, trials and access
Watch More
Global Biopharma CEO/Top Executives COVID-19 Media Briefing (28 May 2020)
On 28 May 2020, IFPMA organised a media briefing on the status of collaboration and risk-sharing to speed up the research, development and manufacturing of vaccines against COVID-19.
Watch more
PHARMA CEO/TOP EXECUTIVES GLOBAL RESPONSE TO COVID-19 - VIRTUAL PRESS BRIEFING
On 30 April 2020, the global biopharmaceutical industry, represented by high-level executives/ CEO’s, took part in a virtual media briefing on the status of COVID-19 treatments
Watch more
Pharma CEO/Top Executives Global Response to COVID-19 – Virtual Press Briefing
On 19 March 2020, the global biopharmaceutical industry, represented by high-level executives/ CEO’s, took part in a virtual media briefing highlighting industry’s efforts and future commitments to address the current global coronavirus (COVID-19) crisis.
Watch more
AMR Action Fund
More than 20 leading pharmaceutical companies launched a ground-breaking collective venture - the AMR Action Fund - to bridge the current gap in funding for the development of new antibiotics
Read More
COVID-19
IFPMA members commit to accelerate their effort to use their skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. Visit IFPMA COVID-19 Hub.
Read More
Meet #GenerationGavi
Over the past 20 years, IFPMA and its members have proudly worked with Gavi, The Vaccine Alliance, to protect the most valuable resource on earth thanks to life saving vaccines: its children.
Read More
IFPMA Code of Practice eLearning
Our Code of Practice has evolved over time and it promotes a culture grounded on values, principles and decisions based on good judgement. You can take our new eLearning here!
Start training hereIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Ethics and Business Integrity
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Discovering medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
IFPMA Code of Practice 2019
Read More
Health for All in Africa - Our collaborations supporting the SDGs
Read More
Message from Thomas Cueni at AMR Action Fund launch event in Tokyo on 10 July 2020 (Video)
Read More
Global Biopharmaceutical Industry pulling out all the stops to address Coronavirus public health crisis
19 March 2020, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the world’s leading biopharmaceutical companies, today confirmed that having already mobilized on an unprecedented scale to respond to the COVID-19 pandemic, they commit to do more. The biopharmaceutical industry commits to accelerate its effort to...
Read More
Greg Perry - IFPMA Moderated Panels @Pre-ICDRA 2018
Read More
Join IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-based
LEARN MOREOur Blog
Interview – BBC World Service Marketplace Morning Report - Vials, syringes, packaging: The small but vital components of COVID-19 vaccine distribution
Thomas Cueni, IFPMA Director General, spoke to BBC World Service Marketplace Morning Report about the efforts and challenges to produce and deliver a vaccine for COVID-19 Victoria Craig One of the keys to getting economies back to some form of normalcy is a vaccine. The US said that it could begin delivering one within 24 hours of FDA approval. But what about the rest of...
Read More
Interview - Asahi TV Japan - Solidarity at the core of COVAX Facility
Interview - Asahi TV Japan - Solidarity at the core of COVAX Facility Thomas Cueni, IFPMA Director General, spoke to Asahi TV in Japan on 18 September 2020 about COVAX and the importance of working together in order to guarantee a safe and effective vaccine in both richer and poorer countries. Here are top 5 points discussed (edited for clarity). What are the merits...
Read More
Interview - BBC World Business Report - Will a coronavirus vaccine reach the developing world?
The biopharmaceutical industry has made addressing the pandemic its top priority, devoting its resources, expertise, know-how, and intellectual assets to developing potential treatments and vaccines at record speed, while committing to and engaging in unprecedented levels of international collaboration and coordination through initiatives such as ACT-A, ACTIV and CEPI to ensure equitable access to products being developed. Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations, had the...
Read MoreLatest Tweets
